The etiologies of optic neuropathy include inflammation, ischemia, toxic and metabolic injury, genetic disease, and trauma. There is little controversy over the practice of using steroids in the treatment of optic neuritis-it is well established that intravenous steroid treatment can speed visual recovery but does not alter final visual function. However, there is controversy surrounding the acceptable routes of administration, dosage, and course of treatment. Additionally, the typical patient with optic neuritis is young and otherwise healthy, and thus is likely to tolerate steroids well. In ischemic and traumatic causes of optic neuropathies, the initial injury is not inflammatory, but damage may be compounded by secondary injury due to resultant inflammation and swelling in the confined space of the optic canal. Steroids have been considered as a means of minimizing inflammation and swelling, and thus minimizing the secondary injury that results. However, the use of steroids in traumatic and ischemic optic neuropathies is highly controversial-the evidence for the efficacy of treatment with steroids is insufficient to show that there is significant benefit. Additionally, patients with these conditions are more likely to have comorbidities that make them vulnerable to significant adverse events with the use of steroids. In this article, we attempt to analyze the current state of the literature regarding the use of steroids in the treatment of optic neuropathies, specifically optic neuritis, nonarteritic anterior ischemic optic neuropathy, and traumatic optic neuropathy.
intracellular receptors, enter the cell nucleus, and affect gene transcription. 6 Corticosteroids, which have both mineralocorticoid and glucocorticoid activity, are relevant to the treatment of optic neuropathies due to their glucocorticoid activity. Glucocorticoids exert an anti-inflammatory effect by both inhibiting the transcription of proinflammatory genes and by upregulating the transcription of anti-inflammatory genes. [6] [7] [8] [9] For optic neuropathy, steroids are typically administered systemically, either orally or intravenously. Prednisone and methylprednisolone are common choices, but systemic dexamethasone and intravitreal triamcinolone have also been explored.
Potential benefits of steroids must be weighed against the risk of possible complications. Side effects are common, with up to 90% of patients who use steroids reporting adverse reactions.
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Adverse events range from mild to life-threatening, including recurrent infection due to immunosuppression, hyperglycemia and drug-induced diabetes mellitus, weight gain, osteoporosis, gastroesophageal reflux disease, hypertension, hyperlipidemia, avascular necrosis of the hip, myopathies, friable skin (dermal atrophy) and acne and skin bruising, slow wound repair, ophthalmologic side effects such as glaucoma and cataracts, and neurologic/ psychiatric side effects such as poor concentration, agitation, insomnia, and behavioral changes. [8] [9] [10] Side effects are dose-and duration-dependent. 8 Life-threatening adverse effects have been reported, including pancreatitis, adrenal insufficiency, metabolic derangements, 8, 9 and susceptibility to serious infections. The rationale for the use of steroids in optic neuropathies varies among the different etiologies. Optic neuritis (both demyelinating and nondemyelinating), in which inflammation is the etiology of the injury, is treated with steroids on the basis of their anti-inflammatory properties. There is little controversy over the practice of using steroids in the treatment of optic neuritis. However, there is controversy surrounding the acceptable routes of administration, dosage, and course of treatment. 11 In other forms of optic neuropathy, the use of steroids at all is more controversial. In ischemic and traumatic causes of optic neuropathies, the initial injury is not inflammatory, but it may be compounded by secondary injury due to resultant inflammation and swelling within the confined space of the optic canal. Steroids are intended to minimize the inflammation and swelling associated with the original injury, and thus prevent the secondary injury.
Reports of improvement with treatment may be confounded by a variety of factors, including placebo effect, response bias (the tendency for patients to report more favorable outcomes and fail to report unfavorable outcomes), spontaneous improvement as part of the natural history of the condition, and regression to the mean (the latter is particularly important for conditions in which spontaneous improvement occurs). Even large case series can be prone to bias due to factors such as lack of randomization, lack of control group, and lack of masked observers. 12, 13 These factors are particularly important when some of the outcomes are psychophysical tests that are dependent upon patient response and cooperation with the test (eg, visual acuity, visual field testing, and so on). Thus, the necessity of critical analysis of the literature.
Humans are prone to mistake correlation for causation-the "post hoc, ergo proptor hoc" fallacy ("after this, therefore because of this"). Major medical organizations have developed a "hierarchy of evidence" as a tool to assess the quality of the extant literature and help physicians make treatment decisions (Table 1) . 14, 15 Randomized, placebo-controlled, double-blind masked studies are the gold standard at the top of the hierarchy but may not be feasible with rare diseases. In such cases, the physician must use the best available evidence in the medical literature and apply it to the individual patient. This does not mean that studies with lower levels of evidence are worthless-they retain value, but the results must be interpreted with a degree of caution until better and confirmative evidence emerges.
In this article, we attempt to analyze the current state of the literature regarding the use of steroids in the treatment of optic neuropathies including optic neuritis, nonarteritic anterior ischemic optic neuropathy (NAION), and traumatic optic neuropathy.
STEROIDS FOR OPTIC NEURITIS
Optic neuritis is an acute to subacute, inflammatory, demyelinating optic neuropathy that presents with visual changes and pain with eye movements. 16, 17 The incidence of optic neuritis has been reported to be as high as 6.4 per 100,000.
18 Optic neuritis is most common in women and more common in the young; it may present in patients ranging from the teenage years to the 50s, but it is most common in the 20s and 30s. 16, 19 The most common association is with multiple sclerosis (MS), 16, 17, 20, 21 but optic neuritis can also be associated with other disorders, such as neuromyelitis optica (NMO), myelin oligodendrocyte glycoprotein antibodies, sarcoidosis, lupus, and others. For the purposes of this review, "optic neuritis" will refer to primary demyelination, either idiopathic or related to MS. Optic neuritis is characterized by changes in visual acuity, visual fields, and color vision. 16, 17, 19, 22, 23 In unilateral cases, the examination will almost always show a relative afferent pupillary defect-in fact, presence of a relative afferent pupillary defect was an inclusion criterion for the Optic Neuritis Treatment Trial (ONTT). 16 In about 30% of cases, the examination will show swelling of the optic disc, but most are retrobulbar, with no visible disc swelling. 16 Magnetic resonance imaging (MRI) may show supportive features such as T2 hyperintensity and enhancement of the optic nerve, but is not required to make the diagnosis.
The natural history of optic neuritis is to improve spontaneously over the course of weeks, as the inflammatory process resolves. 19, 24 After a single occurrence of optic neuritis, final visual acuity will usually recover to normal or very mild residual deficits-in the ONTT, 74% of patients had visual acuity of 20/20 or better in the affected eye 10 years after the optic neuritis episode. Residual deficits are more likely in severe cases, or after subsequent attacks of optic neuritis in the same eye. The ONTT is the largest and most influential trial. The ONTT randomized 448 patients within 8 days of symptom onset into 3 arms: 1) intravenous (IV) methylprednisolone 1 g daily (divided into 4250 mg doses) for 3 days (followed by an 11-day oral prednisone taper), 2) oral prednisone 1 mg/kg daily for 14 days, or 3) oral placebo. Participants were masked to oral prednisone versus placebo but unmasked to IV methylprednisolone. Examiners were masked to treatment. The group that received IV methylprednisolone recovered faster, with better visual function at 2-3 weeks, and slightly better visual function still detectable at 6 months (P = 0.001). However, long-term recovery was the same for all groups. At 1-year and at 10-year follow-up there was no difference. 24, 25, 27, 28 The ONTT also found a higher rate of subsequent optic neuritis attacks in the group treated with oral prednisone. 25, 27 This well-designed, large, randomized study collected data over an impressive 15-year follow-up period. It significantly improved understanding of steroids as a treatment for optic neuritis, and its results had an appreciable effect on practice patterns. 29 Further supporting the validity of the ONTT results, subsequent studies have consistently replicated its results: steroid treatment speeds recovery but does not alter long-term visual outcome. 26, [30] [31] [32] [33] [34] In keeping with these results, Kapoor et al 35 also showed that steroids hasten recovery without changing the final visual outcome, regardless of the length of the optic neuritis lesion. Longer lesions did not exhibit greater benefit from steroids than shorter ones, suggesting that secondary injury from compression is not a significant mechanism of injury in optic neuritis. 35 After the ONTT showed a higher rate of subsequent optic neuritis attacks in the group treated with oral prednisone, guidelines and expert opinions recommended intravenous steroids only. 26, 36 However, the ONTT examined mega dose (1 g daily) intravenous steroids versus regular high-dose (1 mg/kg daily) oral steroids. In 1999, Sellebjerg et al 37 showed that in a placebo-controlled trial of 60 patients, oral methylprednisone 500 mg daily for 5 days followed by a taper increased the speed of visual recovery (P = 0.008), and that after 1 year of follow-up, there was no increase in disease activity in the oral steroid group. 37 A recent, single-blind trial of 55 patients randomized to receive intravenous methylprednisolone (1 g daily) versus a bioequivalent dose of oral prednisone (1250 mg daily) showed no difference in visual outcome after 6 months. 38 Although many optic neuritis patients return to normal or near-normal levels of visual function and are able to resume visual tasks of daily living, some continue to complain of mild residual symptoms. 39 Self-reported visual impairment continues even altitudinal. 19, 54 Fundus examination by definition shows optic disc edema. 19, 52 The mechanism of NAION is thought to be impaired perfusion of the optic nerve head, leading to optic disc edema, resulting in compression of the optic nerve within the canal and further ischemic injury. [56] [57] [58] About 40% of patients with NAION may have spontaneous improvement of 3 or more lines of visual acuity. 53, 55 However, visual fields are less likely to improve spontaneously. 55 There is evidence that optic disc swelling can persist for 6-11 weeks. 59 After the edema resolves, the disc develops pallor.
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Despite being studied for decades, there is no high-quality evidence supporting any treatment for NAION. Myriad treatments have been attempted, including hyperbaric oxygen, allowing the nerve to swell safely (surgical techniques including optic nerve decompression and transvitreal optic neurotomy), decreasing optic nerve swelling (anti-vascular endothelial growth factor agents), decreasing intraocular pressure to improve perfusion (topical brimonidine), preventing platelet aggregation (ie, aspirin), preventing blood clotting (anticoagulants), increasing blood pressure to improve perfusion (norepinephrine), vasodilation (systemic or subtenon administration of vasodilators or stellate ganglion block), neuroprotection (ie, antiepileptic drugs), and promotion of nerve regeneration (transcortical electric stimulation). 53, [60] [61] [62] [63] [64] Currently, there is an ongoing prospective phase 2/3, placebo-controlled, double-masked trial of an siRNA against caspase 2, which is intended to treat NAION by preventing apoptosis. 65 Steroids as a treatment for NAION were first considered in the 1960s. 66 The mechanism of NAION provides a plausible mechanistic reason to explore steroids as a potential therapy: as optic disc edema may contribute to the optic nerve damage, reducing disc edema with steroids might potentially minimize the damage that follows the initial ischemic insult and limit the secondary injury resulting from inflammation, swelling, and further compression of the capillaries in the optic nerve head. 56, 67 Oral steroids, and more recently both intravenous and intravitreal steroids, have been considered (Table 2) . However, more than 50 years after they were first considered for treatment of NAION, steroids remain controversial at best.
In 1970, Foulds 67 reported a case-control study of 60 mg prednisolone daily in 13 patients compared with 11 controls, which showed improvement of visual acuity in 85% of those treated with steroids compared with only 45% of the controls. A 1974 study of oral prednisone 40-80 mg daily in 8 patients compared with 6 controls showed that 75% of the treated patients had improvement in visual acuity compared with 17% of the controls. 56 The largest study of steroids in NAION to date was a series of 236 patients collected from 1973 to 2000, comparing patients who chose to receive a steroid taper starting with prednisone 80 mg daily for 2 weeks with 301 patients who chose to be controls and not receive steroid therapy. The results of the study were promising-visual acuity improved more than 3 Snellen lines in 70% of the steroid-treated group compared with improvement of 40% in the control group (P = 0.001) and visual fields improved in 40% compared with improvement in 24.5% of the controls (P = 0.005). Optic disc swelling resolved more quickly in the steroid-treated group-6.8 weeks versus 8.2 weeks (P < 0.0001).
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The main strength of this study is the large number of 5-8 years after an episode of optic neuritis. 40 Although standard office tests of visual function may be normal, low contrast visual acuity changes may be detectable using Sloan charts, and the changes correlate to poorer self-reported quality of life scores.
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Optic neuritis associated with other disorders, such as NMO, myelin oligodendrocyte glycoprotein antibodies, sarcoidosis, systemic lupus erythematosus, Behcet syndrome, Sjogren syndrome, and others, is described as atypical optic neuritis. Chronic relapsing intermittent optic neuritis (CRION) resembles idiopathic optic neuritis but recurs when steroids are weaned. Concerning features for atypical optic neuritis include very old or very young age, bilateral onset, lack of pain, severe disc edema, hemorrhages, exudates, uveitis, macular star, severe visual loss, atypical disease course (progression for more than 2 weeks, failure to recover after 3 weeks, relapsing after improvement, or relapsing after steroids are stopped), and history of cancer or stigmata of systemic disease. [42] [43] [44] Features on MRI that suggest an alternate diagnosis include posterior or chiasmal optic nerve involvement, or longitudinally extensive optic nerve involvement. 45 Data on the natural history and treatments for atypical optic neuritis are more limited. 42 Treatment varies depending on the underlying condition. Neuromyelitis optica-optic neuritis may improve with steroids, but with a limited response compared with typical optic neuritis, 46 and may require plasma exchange treatments.
44 Sarcoidosis-related optic neuritis and CRION are both exquisitely responsive to steroids and may be dependent on steroids-relapses are common when attempts to wean steroids are made.
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Some commentators have suggested that, in light of the high rate of spontaneous recovery, patients should not be exposed to the risks of steroid treatment. However, the typical populationyoung, healthy women-has a favorable side effect profile for short-term steroid treatment. Side effects reported in studies of steroids for optic neuritis include weight gain, transient mood disturbances (euphoria), insomnia, gastrointestinal upset, facial flushing, and acne. The only severe adverse effects reported in the published studies were acute pancreatitis and psychosis, each reported once out of the 457 patients in the ONTT, and both recovered fully. 17, 34, [47] [48] [49] For some patients with profound visual loss and specific occupational needs, early recovery of visual function and binocularity is enough to warrant the relatively low risk of short-term corticosteroids.
Overall, there is sufficient data to show that mega dose (1 g) intravenous steroid treatment for optic neuritis is a safe treatment to speed recovery of visual function in optic neuritis that does not affect long-term visual recovery, and there is new evidence that bioequivalent doses of mega dose oral steroids can also speed visual recovery in this condition, without increasing the risk of recurrent optic neuritis.
STEROIDS FOR NAION
The incidence of NAION is estimated at around 2-10 per 100,000. 50, 51 Risk factors include a small, crowded disc, along with systemic risk factors such as hypertension, diabetes mellitus, and cerebrovascular disease. [52] [53] [54] [55] Typically, NAION presents with painless, acute-onset, unilateral visual loss, although it can rarely present bilaterally and simultaneously. The visual acuity at onset is variable, ranging from 20/20 to no light perception. 19, [52] [53] [54] [55] Visual field defects are very common 19, 52, 55 and the most common type of visual field defect is altitudinal, 19 ,51,52 particularly inferior IV  III  IV  IV  III  IV  IV  IV  II  III  III  III  III  II patients. However, there are important limitations. The lack of randomization and the lack of blinding raise concerns about bias. The 2 groups were not equivalent at baseline. The control group was older (the mean age was 59.2 in the steroid-treated group and 62 in the control group, P = 0.006) and had more vascular risk factors. Different rates of hypertension-34% versus 43% (P = 0.036)-reached statistical significance. Ischemic heart disease, transient ischemic attack/stroke, and diabetes mellitus were also seen at a higher rate in the control group (but did not reach statistical significance). 68 Hayreh has defended the validity of his results despite the lack of randomization by arguing that the 2 groups are similar enough that the data is useful, pointing specifically to the demographic results as reported above. 69 Furthermore, the data were analyzed using those factors as covariates to minimize their effect on the results. 68, 69 However, it is important to note that even if the 2 groups seem similar in every important way, the aim of randomization is also to produce groups that are the same regarding variables that could never be predicted to have an impact on the results. The lack of placebo control, blinding, or masking in the study is arguably an even more important source of bias. It is unknown to what extent the placebo effect, along with other factors mentioned above (response bias, regression to the mean, and so on), might have influenced patients' recovery as well as their experience of their recovery, especially in a disease that has a natural history of some spontaneous improvement.
Class of Edvience
Since the Hayreh and Zimmerman study in 2008, 68 there have been a few additional studies of oral steroids in NAION. In 2013, a retrospective study of 10 patients who received prednisolone 80 mg daily for 14 days followed by a taper showed no improvement with steroid treatment and showed steroid-related complications in 3 out of the 10 patients. 70 The only randomized study of oral steroids, done in 2013, compared 30 patients randomized to receive fluocortolone therapy as adjuvant to pentoxifylline versus 30 controls who received pentoxifylline alone. Patients treated with steroids had improvement in visual acuity but not visual fields. 62 Visual acuity improvement without corresponding improvement in visual fields has often been called into question due to the fact that the visual acuity improvement may be due to eccentric fixation and not due to structural improvement. 55, 59 There have been only 2 studies of intravenous steroid treatment for NAION. In 2014, a retrospective study found no statistically significant difference comparing 23 patients who received IV methylprednisolone for 3 days followed by a prednisone taper with 23 controls. 71 In 2016, a randomized, placebo-controlled, unmasked trial comparing 30 patients who received IV methylprednisolone for 3 days then prednisone taper against 30 controls also found no statistically significant difference. 63 Despite its flaws, the data collected by the large Hayreh and Zimmerman 68 study cannot be discarded. However, it must be interpreted in light of its limitations and in the context of other available data. If steroids have a positive effect on recovery in NAION, then this effect should be reproducible in other studies. However, other studies have been unable to replicate these results.
More recently, intravitreal steroid injections have been evaluated as a possible route of administration that would allow the patient to have maximal benefit without exposure to the adverse effects of systemic steroids. Small case series showed mixed results and found that ocular hypertension is a potential adverse effect. [72] [73] [74] Two case-control studies have shown improvement. In 2007, Kaderli et al 75 showed improvement in visual acuity but not visual fields in 4 patients who received intravitreal triamcinolone compared with 6 controls. However, the study was criticized because the visual acuity change may have been due to eccentric fixation. In 2014, Radoi et al 76 showed both visual acuity improvement and visual field improvement in 21 patients who received intravitreal triamcinolone compared with 15 controls.
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The debate over steroids for NAION has been limited by small studies, lack of randomization, and difficulty in determining what improvements are truly due to treatment effect in a disease with wide variation in its natural history. The allure of steroids as a treatment is in part due to plausibility and in part due to the fact that there is no proven treatment for patients with NAION. However, the evidence to date would argue against the routine use of corticosteroids for patients with NAION.
STEROIDS FOR TRAUMATIC OPTIC NEUROPATHY
Traumatic optic neuropathy (TON) refers to damage to the optic nerve that occurs due to trauma to the head or the face. The incidence is around 1 per million. 77, 78 Presenting visual acuity is 6/60 or worse in 70% of patients, and 36% of patients may have no light perception. 77 However, the rate of spontaneous recovery may be as high as 40-60%. 79 Worse visual acuity at the time of injury corresponds to worse visual outcomes.
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There are 2 mechanisms of trauma-related injury to the optic nerve-direct and indirect. Direct trauma to the optic nerve refers to an injury that causes mechanical disruption of the nerve, which can be due to a penetrating injury or due to orbital fractures with bone shards lacerating or impinging directly upon the nerve. Indirect trauma to the optic nerve refers to cases in which the nerve is not directly or mechanically injured, but optic neuropathy develops after trauma to the head or face. Indirect trauma is thought to damage the optic nerve due to shearing of the retinal ganglion cell axons in the optic canal. 80 Primary injury is immediate damage due to either direct laceration or compression of the optic nerve or due to shear forces. Secondary injury is delayed-onset damage, thought to be at least in part due to inflammation and subsequent edema within the confined space of the bony canal leading to compression of capillaries and thus ischemic damage. [80] [81] [82] [83] There has been longstanding controversy regarding the best course of treatment for TON. Steroid treatment, the focus of this article, aims to minimize secondary injury due to inflammation and edema. Another common treatment option is surgical decompression of the optic canal, also intended to minimize secondary damage due to swelling. A third option, watchful waiting, is intended to minimize potential harm from those controversial treatments, especially in light of the fact that spontaneous recovery is not uncommon. 79 The idea that steroids may decrease inflammation in TON came from the National Acute Spinal Cord Injury Study (NASCIS). The spinal cord, like the optic nerve, is heavily myelinated and encased in a bony structure that physically limits its ability to swell safely. Steroids for spinal cord injury are intended to prevent or decrease inflammation and swelling and thereby minimize further damage to the spinal cord. The NASCIS was a study of acute spinal cord patients that showed benefit for IV steroids given within 8 hours. It showed that patients who were treated with intravenous steroids within 8 hours of spinal cord injury had better motor and sensory outcomes 6 months later. 
Studies Examining Steroid Treatment in TON

Author (Year)
Lai et al (2016) 93 Ropposch et al (2013) 94 Miliaris et al (2013) 95 Soldevila et al (2013) 96 Ford et al (2012) 78 IV  III  IV  IV  III  IV  III  IV  IV  I IV
Samardzic et al (2012)
Class of Edvience
Results
Receiving steroids within 0-24 hours of injury was correlated with improvement. Steroids had no beneficial effect on visual outcome (P = 0.97). efficacy of steroids in TON (Table 3) . There are few data on the natural history of TON, which makes it difficult to evaluate the effect of treatment and much of the available literature consists of case reports or case series without controls. The International Optic Nerve Trauma Study in 1999 was the earliest controlled study of steroids for TON and showed no improvement due to steroid treatment. However, the study was not randomized, only had 9 patients in the control group, and the steroid doses patients received were quite variable. 86 In 2004, a retrospective study of patients with TON treated with mega dose steroids (the regimen tested in the NASCIS) compared with untreated controls did not show a higher rate of improvement with steroid treatment. However, in patients who did improve, steroid treatment correlated with a greater degree of improvement. This study did not control for whether patients received surgical decompression as well. 87 The only randomized, placebo-controlled trial was unable to show a statistically significant benefit of steroids. In 2007, a randomized, placebo-controlled, double-blinded study of 31 patients showed improvement in visual acuity in 68.8% of the treatment group and 53.3% of the placebo group, but the difference was not statistically significant (P = 0.38).
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Subsequent literature has been limited to case reports and case series. However, despite the lack of strong evidence that steroids are efficacious for TON, steroids continue to be used, often due to individual and institutional preferences. This limits the data available on the natural history of TON.
The urgency of determining whether steroids are efficacious for TON increased with the results of the Corticosteroid Randomisation After Significant Head Injury study, which showed that steroid treatment may increase mortality in patients with traumatic brain injury. 89 All patients with TON by definition have a head injury, and many of them have traumatic brain injuries. Therefore, given the lack of robust evidence of benefit for steroids in TON, the potential risk may outweigh any potential benefit.
Evaluation of steroids as a treatment for TON has also been limited by poor recruitment, variable steroid regimens, recruitment of patients at variable time limits after injury, the broad range of severity seen in TON, and variable comorbidities of patients. Furthermore, surgical decompression may also confound analysis of the effects of steroids. Traumatic optic neuropathy is a complicated disorder and there are not yet sufficient data on whether steroids improve visual outcomes. It is important to improve understanding of the possible benefits of steroids for optic neuropathy in light of the risks of steroid treatment in patients with head injuries.
CONCLUSIONS
The optic neuropathies described above all have a natural history of (varying degrees of) acute to subacute onset of visual disturbance, often followed by slow improvement, even without treatment. This makes it particularly difficult to analyze the efficacy of treatments for these disorders. When studying conditions that may improve spontaneously, it is particularly important to have a matched control group to avoid confounding, as discussed above. These conditions may manifest with a variety of severities at initial presentation, complicating analysis of treatment efficacy. Traumatic optic neuropathies and NAION are particularly complicated in that a single optic nerve injury may have more than 1 mechanism of injury contributing to the manifested visual loss.
The complicated mechanism of these optic neuropathies makes it less surprising that large clinical trials have found unexpected results-for example, the ONTT finding that treatment does not impact final visual outcome and that treatment with oral steroids is associated with an increased incidence of recurrence of optic neuritis. This demonstrates the value of doing large, randomized clinical trials to evaluate for unexpected outcomes and control for unforeseeable variables.
For optic neuritis, it is well established that intravenous steroid treatment can speed visual recovery but does not alter final visual function. Oral steroids, which have long been avoided in optic neuritis out of concern that they may increase the risk of recurrence, have recently been shown to speed visual recovery when given at doses bioequivalent to intravenous treatment doses without increasing recurrence rates over a 6-month follow-up period. Additionally, the typical patient with optic neuritis is young and otherwise healthy, and thus likely to tolerate steroids well. For traumatic and ischemic optic neuropathies, the evidence for the efficacy of treatment with steroids is insufficient to show that there is significant benefit. Additionally, patients with these conditions are more likely to have comorbidities-head injury in the case of TON and metabolic and vascular disease in the case of NAION-that make them more likely to have significant adverse events with the use of steroids. The use of corticosteroids for TON and NAION remains unproven and the individual physician must decide whether to use these treatments on a case-by-case basis, weighing the risk against any potential benefit.
